ObesityWeek® 2025 Resource Hub –
Welcome to our resource hub for ObesityWeek® 2025! This is a one-stop-shop for all your ObesityWeek® 2025 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.
Useful Conference Links
Day-of Conference Reports
Top Highlights
- Presidential Plenary: Drs. Daniel Bessesen, James Hill, and Robert Eckel on obesity as a chronic disease
- Drs. Robert Kushner, Fatima Cody Stanford, and Donna Ryan debate the clinical use of the Lancet Commission’s new obesity definition
- Weight loss and metabolic benefits maintained with de-escalation of semaglutide and tirzepatide
- A reduction in muscle inflammation may explain muscle mass loss with GLP-1 RAs and may provide protective effects
- Prior weight loss attenuated tirzepatide response, except in people with T2D
- Full results of the phase 3 ATTAIN-2 trial: Lilly’s once-daily oral GLP-1 RA orforglipron reduces weight by up to 11% and A1c by up to 1.8% in participants T2D and overweight or obesity
- STEP UP trial post-hoc analysis: 13-20% of participants achieved a low risk cardiometabolic state in 72 weeks with semaglutide use
- Key Lecturers: Dr. Lotte Bjerre Knudsen and Dr. Philipp Scherer discuss GLP-1 RAs and adiponectin over the ages
- Post-hoc analysis of the OASIS-4 trial: Participants demonstrating ≥15% weight reduction experienced improved glycemic management and cardiovascular benefits
- Post-hoc analysis of SURMOUNT-5: Participants with limited physical function at baseline experienced higher quality of life scores on tirzepatide versus semaglutide when assessed by SF-36v2
- Full results of the phase 2 trial: Amylin agonist eloralintide confers up to 20% weight loss in people with obesity
- Post-hoc analyses of REDEFINE 1: CagriSema reduces blood pressure in adults with overweight or obesity and positively affects body composition
- Key Lecturers: Dr. Ziyad Al-Aly maps the neurological effectiveness and risks of GLP-1 RAs
- Dr. Louis Aronne delivers George A. Bray Founders Award lecture on the past, present, and future of medical treatment of obesity
- Prof. Stephen O’Rahilly spotlights subcutaneous adipose tissue as an important therapeutic target for metabolic syndrome
- Phase 2b QUALITY trial of enobosarm shows that combination therapy with a GLP-1 RA is selective for fat loss while preserving lean mass and function
- Medicare GLP-1 RA prescription disparities: One-third of beneficiaries are eligible, yet only 5% have a claim for a GLP-1 RA